miRNA Delivery by Nanosystems: State of the Art and Perspectives - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Pharmaceutics Année : 2021

miRNA Delivery by Nanosystems: State of the Art and Perspectives

Résumé

MicroRNAs (miRNAs) are short (~21–23 nucleotides), non-coding endogenous RNA molecules that modulate gene expression at the post-transcriptional level via the endogenous RNA interference machinery of the cell. They have emerged as potential biopharmaceuticals candidates for the treatment of various diseases, including cancer, cardiovascular and metabolic diseases. However, in order to advance miRNAs therapeutics into clinical settings, their delivery remains a major challenge. Different types of vectors have been investigated to allow the delivery of miRNA in the diseased tissue. In particular, non-viral delivery systems have shown important advantages such as versatility, low cost, easy fabrication and low immunogenicity. Here, we present a general overview of the main types of non-viral vectors developed for miRNA delivery, with their advantages, limitations and future perspectives.
Fichier principal
Vignette du fichier
2021_moraes_pichon_pharmaceutics.pdf (1.6 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03470645 , version 1 (08-12-2021)

Identifiants

Citer

Fernanda Moraes, Chantal Pichon, Didier Letourneur, Frédéric Chaubet. miRNA Delivery by Nanosystems: State of the Art and Perspectives. Pharmaceutics, 2021, 13 (11), pp.1901. ⟨10.3390/pharmaceutics13111901⟩. ⟨hal-03470645⟩
64 Consultations
77 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More